Literature DB >> 21757183

System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial).

Peter H Nielsen1, Christian J Terkelsen, Torsten T Nielsen, Leif Thuesen, Lars R Krusell, Per Thayssen, Henning Kelbaek, Ulrik Abildgaard, Anton B Villadsen, Henning R Andersen, Michael Maeng.   

Abstract

The interval from the first alert of the healthcare system to the initiation of reperfusion therapy (system delay) is associated with mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (pPCI). The importance of system delay in patients treated with fibrinolysis versus pPCI has not been assessed. We obtained data on system delay from the Danish Acute Myocardial Infarction-2 study, which randomized 1,572 patients to fibrinolysis or pPCI. The study end points were 30-day and 8-year mortality. The short system delays were associated with reduced absolute mortality in both the fibrinolysis group (<1 hour, 5.6%; 1 to 2 hours, 6.9%; 2 to 3 hours, 9.5%; and >3 hours, 11.5%; test for trend, p = 0.08) and pPCI group (<1 hour, not assessed; 1 to 2 hours, 2.6%; 2 to 3 hours, 7.5%; >3 hours, 7.7%; test for trend, p = 0.02). The lowest 30-day mortality was obtained with pPCI and a system delay of 1 to 2 hours (vs fibrinolysis within <1 hour, adjusted hazard ratio 0.33; 95% confidence interval 0.10 to 1.10; p = 0.07; vs fibrinolysis within 1 to 2 hours, adjusted hazard ratio 0.37; 95% confidence interval 0.14 to 0.95; p = 0.04). pPCI and system delay >3 hours was associated with a similar 30-day and 8-year mortality as fibrinolysis within 1 to 2 hours. In conclusion, short system delays are associated with reduced mortality in patients with ST-segment elevation myocardial infarction treated with fibrinolysis as well as pPCI. pPCI performed with a system delay of <2 hours is associated with lower mortality than fibrinolysis performed with a faster or similar system delay.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757183     DOI: 10.1016/j.amjcard.2011.05.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection.

Authors:  Vikas Singh; Mauricio G Cohen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05

2.  Efficacy and limitations of a STEMI network: 3 years of experience within the myocardial infarction network of the region of Augsburg - HERA.

Authors:  Christian Thilo; Andreas Blüthgen; Wolfgang von Scheidt
Journal:  Clin Res Cardiol       Date:  2013-09-06       Impact factor: 5.460

3.  Reperfusion delay in patients treated with primary percutaneous coronary intervention: insight from a real world Danish ST-segment elevation myocardial infarction population in the era of telemedicine.

Authors:  Mikkel M Schoos; Maria Sejersten; Anders Hvelplund; Mette Madsen; Jacob Lønborg; Jacob Steinmetz; Philip M Treschow; Frants Pedersen; Erik Jørgensen; Peer Grande; Henning Kelbæk; Peter Clemmensen
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-09

4.  Strategies TO reduce time delays in patients with AcuTe coronary heart disease treated with primary PCI--the STOP WATCH study: a multistage action research project.

Authors:  Tim Tödt; Ingela Thylén; Joakim Alfredsson; Eva Swahn; Magnus Janzon
Journal:  BMJ Open       Date:  2013-09-03       Impact factor: 2.692

5.  Patients with ST-segment elevation of myocardial infarction miss out on early reperfusion: when to undergo delayed revascularization.

Authors:  Wen Zheng; Cheuk-Man Yu; Jing Liu; Wu-Xiang Xie; Miao Wang; Yu-Jiao Zhang; Jian Sun; Shao-Ping Nie; Dong Zhao
Journal:  J Geriatr Cardiol       Date:  2017-08       Impact factor: 3.327

Review 6.  Unmet goals in the treatment of Acute Myocardial Infarction: Review.

Authors:  Alejandro Farah; Alejandro Barbagelata
Journal:  F1000Res       Date:  2017-07-27

7.  Frequency of Thrombolysis in Myocardial Infarction III Flow in Patients With Primary Percutaneous Coronary Intervention: Not All Culprit Vessels Are Completely Occluded in ST Elevation Myocardial Infarction.

Authors:  Muhammad Hussain; Rajesh Kumar; Ali Ammar; Syed Alishan; Atif S Muhammad; Fawad Farooq; Tahir Saghir; Naveedullah Khan; Syed N Hassan Rizvi; Tariq Ashraf
Journal:  Cureus       Date:  2020-12-12

8.  Fibrinolysis Therapy Combined with Deferred PCI versus Primary Angioplasty for STEMI Patients During the COVID-19 Pandemic: Preliminary Results from a Single Center.

Authors:  Jing Nan; Shuai Meng; Hongyu Hu; Ruofei Jia; Zening Jin
Journal:  Int J Gen Med       Date:  2021-01-19

9.  Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy.

Authors:  Kaiyin Li; Bin Zhang; Bo Zheng; Yan Zhang; Yong Huo
Journal:  Front Cardiovasc Med       Date:  2022-03-17

10.  Prehospital Activation of Hospital Resources (PreAct) ST-Segment-Elevation Myocardial Infarction (STEMI): A Standardized Approach to Prehospital Activation and Direct to the Catheterization Laboratory for STEMI Recommendations From the American Heart Association's Mission: Lifeline Program.

Authors:  Michael C Kontos; Michael R Gunderson; Jessica K Zegre-Hemsey; David C Lange; William J French; Timothy D Henry; James J McCarthy; Claire Corbett; Alice K Jacobs; James G Jollis; Steven V Manoukian; Robert E Suter; David T Travis; J Lee Garvey
Journal:  J Am Heart Assoc       Date:  2020-01-20       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.